Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer.

Autor: Allegretti M; Oncogenomics and Epigenetics, IRCSS Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144, Rome, Italy., Fabi A; Medical Oncology 1, IRCSS Regina Elena National Cancer Institute, Rome, Italy.; Present Address: Precision Medicine Breast Cancer Unit, Scientific Directorate, Health of Woman and Child Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy., Giordani E; Oncogenomics and Epigenetics, IRCSS Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144, Rome, Italy., Ercolani C; Pathology, IRCSS Regina Elena National Cancer Institute, Rome, Italy., Romania P; Oncogenomics and Epigenetics, IRCSS Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144, Rome, Italy., Nisticò C; Medical Oncology 1, IRCSS Regina Elena National Cancer Institute, Rome, Italy., Gasparro S; Medical Oncology 1, IRCSS Regina Elena National Cancer Institute, Rome, Italy., Barberi V; Specialization School in Oncology, Sapienza University of Rome, Rome, Italy., Ciolina M; Radiology and Diagnostic Imaging, IRCSS Regina Elena National Cancer Institute, Rome, Italy., Pescarmona E; Pathology, IRCSS Regina Elena National Cancer Institute, Rome, Italy., Giannarelli D; Biostatistical Unit, IRCSS Regina Elena National Cancer Institute, Rome, Italy., Ciliberto G; Scientific Direction, IRCSS Regina Elena National Cancer Institute, Rome, Italy., Cognetti F; Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy., Giacomini P; Oncogenomics and Epigenetics, IRCSS Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144, Rome, Italy. patrizio.giacomini@ifo.gov.it.
Jazyk: angličtina
Zdroj: Molecular cancer [Mol Cancer] 2021 Nov 29; Vol. 20 (1), pp. 151. Date of Electronic Publication: 2021 Nov 29.
DOI: 10.1186/s12943-021-01438-z
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje